BMAC guidelines · References

Evaluating Clinical Outcomes of Recombinant Human Bone Morphogenetic Protein-2 with ECM and BMAC for Ankle Osteochondral Lesions with Subchondral Damage

Foot & Ankle Orthopaedics · 2025

In brief

A retrospective case series reviewed patients whose ankle osteochondral lesions with damage to the underlying bone were repaired using recombinant bone morphogenetic protein, extracellular matrix and bone marrow aspirate concentrate (BMAC). The authors report improved function and pain scores at over a year and a low complication rate, but there was no comparison group.

Read the original paper (opens in a new tab)

Citation, as listed in the BMAC guidelines

27. Evaluating Clinical Outcomes of Recombinant Human Bone Morphogenetic Protein-2 with ECM and BMAC for Ankle Osteochondral Lesions with Subchondral Damage. Foot & Ankle International (SAGE). 2025. https://journals.sagepub.com/doi/10.1177/24730114251398507

A summary of published research for general information. It does not replace a consultation; whether a treatment suits you is decided by a specialist after examination.

More from the BMAC guidelines

Ready to rewrite your health story?

Request a callback from our team.